NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,447.99 +240.86 (+1.32%) CRUDE OIL
79.21 +0.26 (+0.33%) GOLD FUTURES
2,315.40 +5.80 (+0.25%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,495.96 +1,885.77 (+4.13%)
Nkarta, Inc. (NKTX)
After hours:
| Previous close | 7.49 |
| Open | 7.63 |
| Bid | 7.47 x 100 |
| Ask | 7.63 x 100 |
| Day's range | 7.25 - 7.77 |
| 52-week range | 1.28 - 16.24 |
| Volume | |
| Avg. volume | 994,040 |
| Market cap | 530.621M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nkarta to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Inves
- GlobeNewswire
Nkarta Announces Pricing of $240 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for
- GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX1012023 year-end cash, cash equivalents and investments of $250.9 million Cash runway anticipated to fund operations into
